The effect of a magnesium supplement on arterial calcification and arterial stiffness in individuals with type 2 diabetes

Magnesium supplementation as a strategy to reduce serum calcification propensity and vascular stiffness in people with type 2 diabetes: a double-blind, randomized, placebo-controlled parallel trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN60460377

Enrollment

Registered

2023-07-28

Start date

2023-09-06

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular stiffness in people with type 2 diabetes Circulatory System

Interventions

The goal is to investigate the effect of daily intake of 350 mg of magnesium citrate oral supplementation over a period of 6 months on serum calciprotein particle maturation time (T50), a measure of c

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 50-80 years 2. T2D 3. Presence of a predominantly MAC pattern on the CT scan 4. c-f PWV >12 m/s 5. Ability to provide informed consent prior to initiating screening visit procedures

Exclusion criteria

Exclusion criteria: 1. Myasthenia gravis 2. Use of medications that might interact with magnesium supplements (levothyroxine, osteoporosis medications tiludronate and alendronate, warfarin) 3. Advanced diabetes complications: 3.1. Proliferative retinopathy 3.2. Disabling polyneuropathy 3.3. Nephropathy with an estimated glomerular filtration rate (eGFR), calculated with the Jaffé method according to the Chronic Kidney Disease Epidemiology Collaboration equation 2.6 mg/dl at screening

Design outcomes

Primary

Measure	Time frame
1. Serum T50 measured using nephelometry at 3 and 6 months after baseline 2. Carotid-femoral pulse wave velocity (c-f PWV) measured using applanation tonometry at 3 and 6 months after baseline	—

Secondary

Measure	Time frame
1. Total magnesium measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 3 and 6 months after baseline 2 Sodium measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 3. Potassium measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 4. Calcium measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 5. Phosphate measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 6. Urea measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 7. Total protein measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 8. Creatinine measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 9. Triglycerides measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 10. Total cholesterol measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 11. LDL-cholesterol measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 12. HDL-cholesterol measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 13. Fasting plasma glucose measured in NaF vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 14. HbA1C measured in EDTA vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline	—

Measure

Time frame

1. Total magnesium measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 3 and 6 months after baseline 2 Sodium measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 3. Potassium measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 4. Calcium measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 5. Phosphate measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 6. Urea measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 7. Total protein measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 8. Creatinine measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 9. Triglycerides measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 10. Total cholesterol measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 11. LDL-cholesterol measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 12. HDL-cholesterol measured in heparin vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 13. Fasting plasma glucose measured in NaF vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline 14. HbA1C measured in EDTA vials using standard laboratory tests at the Dijklander Hospital Laboratorium at 6 months after baseline

—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 17, 2026